Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)‘s stock had its “outperform” rating reissued by analysts at Ifs Securities in a research note issued to investors on Monday.
A number of other research firms have also weighed in on RNN. FBR & Co set a $14.00 target price on shares of Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 26th. HC Wainwright reissued a “buy” rating and set a $19.50 target price on shares of Rexahn Pharmaceuticals in a research report on Monday, May 22nd. Zacks Investment Research lowered shares of Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, Rodman & Renshaw reissued a “buy” rating and set a $19.50 target price on shares of Rexahn Pharmaceuticals in a research report on Friday, June 9th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.31.
Shares of Rexahn Pharmaceuticals (RNN) opened at 1.82 on Monday. The firm’s market capitalization is $46.27 million. Rexahn Pharmaceuticals has a 52 week low of $0.38 and a 52 week high of $7.10. The stock’s 50 day moving average price is $2.42 and its 200 day moving average price is $1.64.
A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Renaissance Technologies LLC increased its position in shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) by 52.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,896,391 shares of the company’s stock after buying an additional 1,694,398 shares during the period. Renaissance Technologies LLC owned approximately 2.06% of Rexahn Pharmaceuticals worth $695,000 as of its most recent SEC filing.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.